| FiercePharma: Pharma |
|---|
| Novartis slaps $2M-plus pricetag on newly approved gene therapy Zolgensma—and cost watchdogs approve |
| Fri, 24 May 2019 17:32:16 +0000 |
| Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma—and just how payers would cover the "transformative" spinal muscular atrophy treatment. Now they have their answers. |
| Purdue funneled money to nonprofits, WHO employees to sway opioid guidance: report |
| Fri, 24 May 2019 14:10:38 +0000 |
| Since its inception in 1948, the World Health Organization’s role has been, in part, to provide international prescribing guidance without an eye on profits. But what happens when a fox is let loose in the henhouse, and that guidance is tainted by private money? |
| Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm |
| Fri, 24 May 2019 14:06:55 +0000 |
| After 19 salespeople resigned from Amgen last year to join Karyopharm, which is preparing to launch a rival multiple myeloma drug, Amgen sued, alleging theft of trade secrets. Now, as it awaits an FDA decision on its multiple myeloma drug selinexor, Karyopharm is fighting to get the suit thrown out. |
| FiercePharmaAsia—Shingrix's Chinese nod; Chugai's $1B R&D site; Lilly's Verzenio safety woes |
| Fri, 24 May 2019 11:02:12 +0000 |
| GlaxoSmithKline's Shingrix wins nod to tackle China but won't launch until 2020; Roche's Chugai plunks down $1 billion for a new R&D site in Japan; Eli Lilly's oncology rising star Verzenio faces a safety warning in Japan; and more. |
| GSK tweaks ethics-based rep compensation rules to recruit and retain talent |
| Thu, 23 May 2019 15:40:54 +0000 |
| GlaxoSmithKline has the strictest sales pay rules in the industry, thanks to changes it made over the last several years to improve ethics and transparency. But it's loosening up. As of Thursday, the company will allow specialty salespeople to take home bigger paychecks. |
| Want bang for your buck? Don't look to Sarepta's pricey DMD therapy Exondys, ICER says |
| Thu, 23 May 2019 14:31:14 +0000 |
| As far as troubled backstories go, Sarepta Therapeutics’ Exondys 51 has a doozy with a contentious approval process and a major insurer backing away from the targeted therapy. Now the pricey Duchenne muscle dystrophy (DMD) treatment has a new problem: An influential gatekeeper says it simply isn’t cost-effective. |
| Daiichi Sankyo looking to sell OTC business for $900M? 'Not correct,' says company |
| Thu, 23 May 2019 13:31:11 +0000 |
| Is Daiichi Sankyo following in several Big Pharma companies’ footsteps out the consumer healthcare door? That's the word on the street. But according to the company, the answer is "no." |
| J&J's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost |
| Thu, 23 May 2019 13:22:14 +0000 |
| When it comes to Invokana sales, Johnson & Johnson needs a way to stop the bleeding. And it just got one step closer to a new indication in chronic kidney disease—a distinction its rival SGLT2 drugs don't have. |
| Novartis CEO says Zolgensma won't cost anywhere near the $4M to $5M once quoted |
| Thu, 23 May 2019 13:11:16 +0000 |
| Novartis made headlines last year by saying its forthcoming spinal muscular atrophy gene therapy could be cost-effective at up to $5 million. Now, its CEO says the price will be "far lower" than that range. |
| Boehringer Ingelheim plans 3-year, $84M expansion in Mexico |
| Thu, 23 May 2019 12:04:53 +0000 |
| Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years, starting with its site near Mexico City where it makes diabetes drugs. |
| Dendreon commits to prostate cancer vaccine Provenge with new lease for manufacturing site |
| Thu, 23 May 2019 02:03:04 +0000 |
| Dendreon, which last summer changed ownership for a third time in as many years, signaled its faith in prostate drug Provenge by signing a lease extension for its Seal Beach, California, manufacturing facility and headquarters. |
| Array's ‘extremely compelling’ new colon cancer data spark blockbuster talk |
| Wed, 22 May 2019 14:49:17 +0000 |
| Array Biopharma saw its shares soar on interim data for its three-part therapy in BRAF-positive colon cancer. But analysts say the company still needs to prove that the therapy is safe and that its benefits are durable. |
| Lilly to insulin pricing critics: Check out our 50%-off Humalog copy instead |
| Wed, 22 May 2019 14:01:36 +0000 |
| With Congress railing against rising list prices for insulin, Eli Lilly made a commitment to introduce a cheaper generic version of its Humalog in a show of good faith. Consider that a promise kept. |
| Daiichi Sankyo comes up far short of promised avian flu vaccine production |
| Wed, 22 May 2019 13:54:13 +0000 |
| Daiichi Sankyo is apologizing to the Japanese people. The drugmaker is sorry for again missing a deadline to manufacture enough bird flu vaccine to help protect the country in case of an epidemic. It is still coming up far short of being able to produce within six months enough doses to vaccinate 40 million people. |
| J&J's good news, bad news day in talc court yields win in South Carolina, $25M loss in New York |
| Wed, 22 May 2019 13:24:21 +0000 |
| As Johnson & Johnson continues to defend itself against allegations its talc powders can cause cancer, the company prevailed in a South Carolina trial and lost in New York on Tuesday. |
| GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China |
| Wed, 22 May 2019 13:19:03 +0000 |
| GlaxoSmithKline’s shingles vaccine Shingrix has continuously impressed industry watchers with its explosive growth. Now, the company has added another large market to its list: China. |
| Baltimore sues J&J for spinning up a 'sham' Zytiga patent to fend off generics |
| Tue, 21 May 2019 15:30:43 +0000 |
| Johnson & Johnson's blockbuster cancer drug Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to keep copycat rivals at bay. |
| WuXi to build dedicated vaccine facility, but who's the client? |
| Tue, 21 May 2019 14:43:33 +0000 |
| WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t say who the client is. |
| Supreme Court puts Merck's FDA preemption argument up for another review |
| Tue, 21 May 2019 14:00:26 +0000 |
| Merck's Fosamax fight has lasted for years—and thanks to the U.S. Supreme Court, Merck now gets another chance to press its case. But the case also centers on a question the entire pharma industry would like resolved: Whether FDA labeling decisions shield drugmakers from liability in state court. |
| See you in court: Mallinckrodt takes on feds to fight $600M in back Acthar rebates |
| Tue, 21 May 2019 13:41:13 +0000 |
| Mallinckrodt’s Acthar Gel is no stranger to controversy. Pricing critics, payers, and the feds have all targeted the controversial hormone injection. But now, Medicaid is hitting Acthar where it hurts most—in the pocketbook—and the company is more than happy to go to court. |
| rssfeedwidget.com |